Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. by Gold, L S et al.
Environmental Health Perspectives
Vol. 79, pp. 259-272, 1989
Summary of Carcinogenic Potency and
Positivity for 492 Rodent Carcinogens in
the Carcinogenic Potency Database
by Lois Swirsky Gold,* Thomas H. Slone,* and
Leslie Bernsteint
A tabulation of carcinogenic potency (TD50) by species for 492 chemicals that induce tumors in
rats or mice is presented. With the use of the Carcinogenic Potency Database, experimental results
are summarized by indicating in which sex-species groups the chemical was tested and the respective
evaluations of carcinogenicity. A comparison of three summary measures ofTD50 for chemicals with
more than one positive experiment per species shows that the most potent TD50 value is similar to
measures that average values or functions of values. This tabulation can be used to investigate
associations between rodent potency and other factors such as mutagenicity, teratogenicity, chemical
structure, and human exposure.
Introduction
For a variety of purposes it is desirable to have a
summary measure of the carcinogenic potency of a
chemical in rodents. A single value is needed, for
example, to summarize the chronic toxicity of a
chemical, to estimate carcinogenic hazards to humans
by a comparison of rodent potency and human ex-
posure (1,2), or to compare results of short-term tests
with those of rodent bioassays (3). For several years we
have been developing the Carcinogenic Potency
Database (CPDB), a compilation of the results of
chronic rodent cancer tests and the potency values
derived from those results (4-6). The CPDB contains
data on approximately 3700 experiments of 975 com-
pounds, including tests from the National Cancer
Institute and National Toxicology Program (NCI/
NTP), as well as from the general published literature.
For a given compound, the database may include
experiments in both rats and mice, males and females,
a variety of strains or routes of administration, and a
variety of doses and experimental conditions; alter-
natively, for a different substance there may be only
one experiment conducted in a single sex-species
group. In order to construct a chemical-by-chemical
list of carcinogenic potency in each species, some
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method must be selected to summarize the potency of a
carcinogen when there is more than one potency
estimate for it. Additional information to summarize
the experimental results includes the number of sex-
species groups tested and the evaluations of carcino-
genicity in each group.
In this paper we present a table summarizing car-
cinogenic potency in rats and mice for the 492 chem-
icals that have positive results in the CPDB; we also
indicate in which sex-species groups the chemical was
tested and the respective evaluations ofcarcinogenicity.
Our intent is that this summary compilation will be a
useful reference source for the scientific and regulatory
communities, and that it will facilitate the use of our
larger published plots of the CPDB. The larger plots
provide detailed information on each experiment
including the species, sex, strain, route of
administration, duration of exposure and of experi-
ment, dose levels, target sites, shape ofthe dose response,
estimates of carcinogenic potency and the confidence
limits surrounding it, statistical significance of the
carcinogenic dose response, tumor incidences, and
bibliographic citation to the published paper or to the
NCI/NTP Technical Report.
Methods
Our analyses are based on the chemicals reported in
the CPDB (4-6), which has been fully described inGOLD, SLONE, AND BERNSTEIN
Gold et al. (4) as to bioassay inclusion criteria, protocol
characteristics and derived variables. The database is
organized by chemical using a plot format and in-
cludes bioassay results from two sources: papers pub-
lished in the general literature through 1984, and
NCI/NTP Technical Reports published through May
1986. All experiments in the database meet a specific set
of inclusion criteria that were designed to permit the
estimation of carcinogenic potency; therefore, reason-
able consistency of experimental protocols is assured.
Rodent bioassays are included in the database only if
the test agent was administered alone rather than in
combination with other substances; if the bioassay in-
cluded a control group; if the route of administration
was either diet, water, gavage, inhalation, IV injection
or IP injection; and if the length of experiment in
rodents was at least 1 year with dosing for at least 6
months. For the CPDB, we do not evaluate the evidence
for carcinogenicity in an experiment; rather, we report
the evaluation of the published author and calculate
the statistical significance of the tumorigenic dose
response in the experiment.
Carcinogenicity
Our tabular compilation of results by sex-species
group and of carcinogenic potency by species is
restricted to chemicals identified as carcinogens in our
database. We classify the results of an experiment as
either positive or negative on the basis of the author's
opinion in the published paper, and we include in the
present publication only those chemicals that have
been evaluated as positive by the author of at least one
experiment. In some cases authors do not clearly state
their evaluation, and in some NCI/NTP Technical
Reports the evidence for carcinogenicity is considered
only suggestive; in our analyses we consider these
cases as lacking clear evidence of carcinogenicity and
do not use them to identify a chemical as positive. We
use the author's opinion to determine positivity
because it often takes into account more information
than statistical significance alone, such as historical
control rates for particular sites, survival and latency,
and/or dose response. Generally, this designation by
author's opinion corresponds well with the results of
statistical tests for the significance of the dose-response
effect (4,7).
In our tabular compilation of positivity by sex-
species group for each ofthe 492 chemicals classified as
positive, we indicate whether the compound was tested
in each group and list the strongest level ofevidence for
carcinogenicity based upon any author's evaluation
in either the general literature or the NCI/NTP. The
strongest evaluation is clear evidence of carcino-
genicity (+). When there was no such evaluation in
one of the sex-species groups, but the compound was
tested by NCI/NTP and their evaluation was stronger
than "no evidence of carcinogenicity" (-), we indicate
whether that NCI/NTP evaluation was "some evi-
dence of carcinogenicity" (A), "equivocal" (E) or "in-
adequate bioassay" (I). These evaluations correspond to
the opinions reported in our published plots; we note
that in a few borderline cases our interpretation of the
Technical Reports differs from those recently tabulated
by Haseman et al. (8).
Carcinogenic Potency Values
In our analyses of carcinogenic potency we use our
numerical index, the TD50, which has been fully
described in Sawyer et al. (9) and in Peto et al. (10), and
which is reported for each target site in our published
plots. Briefly, TD50 may be defined as follows: For a
given target site(s), TD50 is the chronic dose rate in
milligrams per kilogram body weight per day that
would induce tumors in half the test animals at the
end of a standard lifespan for the species in the absence
of tumors in control animals. Since the tumor(s) of
interest often occurs in control animals, TD50 is more
precisely defined as the chronic dose rate that will
halve the probability of remaining tumor-free
throughout the standard lifespan of the species (9,10).
For bioassays from the NCI/NTP program, TD50
values are estimated from li-fetable data (11) and are
adjusted for the differential effects of toxicity among
dose groups and for differences in the time pattern of
tumor incidence. For experiments from the general
literature, TD50 values are based on summary inci-
dence data [for a comparison of methods and TD50
values see (9,11)]. The range of TD50 values for car-
cinogens in the CPDB is more than 10 million-fold.
For the purposes of this summary, in any given
positive experiment we select the lowest TD50 value
from among positively evaluated target sites with a
statistically significant dose response (two-tailed
p < 0.1). If no positive sites have a significant dose
response, then we select the most potent (lowest TD50)
from among positively evaluated sites with p . 0.1.
This method provides a single TD50 to represent an
experiment. For approximately one-half of the
carcinogens in rats and one-third of the carcinogens
in mice, the CPDB includes only one positive
experiment. For chemicals with more than one
positive test, we summarize potency in a species by
selecting the lowest significant TD50 value from
among those representing each experiment. If none is
significant, the lowest is chosen from among these
nonsignificant values. In some experiments, no TD50
could be estimated because all animals in the only dose
group had the tumor of interest, and the only data
available were for crude percentages of animals with a
tumor (4). For these cases we use the 99% upper
confidence limit ofTD50 as a replacement for theTD50.
Results
InTable 1 we report results for the 492 test agents that
were evaluated by a published author as tumorigenic
in at least one experiment. These are the 492 positive
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Table 1. Carcinogenic potency in mg/kg/day (TD50) and positivity in rats
and mice for chemicals evaluated as carcinogens in at least one experiment.
MR FR MM FM CAS Name
NTF NTI' + + 16568-02-8
+ + + - 60-:35-5
- NT + + 10:3-90-2
NT + NT NT 1852:3-69-8
+ - NT NT 12 -06-0
+ NT - NT :34627 - 78-6
NT N'I' + + 657:34-.38-5
NT NT + + 1078-:38-2
NT NT + + 114-83-0
NT + NT NT 4075-79-0
+ + + + 5:3-96-3
+ + I I 7008-42-6
+ + NT N'I' 107,-1:3-1
+ + NT NT' 50-76-0
+ + + + 3688-5:3-7
+ NT NT NTI' 29611-0:3-8
+ + - - 1162-65-8
+ NT + NT' ---
- - + 13+ :309-00-2
+ A - - 57 -06-7
+ - - + 28:35-:39-4
N'I' NT + + 52207) -8:3-7
NT NT + + 73104-43-7
- - + - 170'26-81-2
+ + + + mixture
N'I' NT + + 68006-8:3-7
+ + + 72254-58-1
+ + - + 82-28-0
+ + + + 677:30-11-4
NT NT + + 76180-96-6
Nl' + NT NT' 37 35-35-1
N'T' + NT N'I' 712-68-5
NT + NT + :38514- 71-35
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MR FR MM FM
B+ B+ + -
NT NT + +
NT NT - +
_ - A +
_ _ + +
NT NT + -
NT NT NT +
NT NT NT +
+ NT + +
+ NT NT NT
NT NT + -
+ + NT NT
E A + +
+ + E -
+ + NT NT
+ + _-
- + NT NT
NT NT + +
NT NT + +
+ NT NT NT
+ + NT NT
+ + B- B-
+
NT NT + +
NT NT + +
NT NT + +
NT + NT NT
NT NT + +
NT NT + +
NT NT + +
B+ B+ - -
NT NT + +
+ + + +
+ + NT NT
+ B+ NT NT
A +
+ NT + +
_ _ + +
+ + + +
- E + E
+ NT - +
+ NT NT NT
- NT + +
- NT + +
+ - - +
+ + + +
_ - + +
_ + +
+ NT + NT
+ NTNT +
_ - + +
+ - + +
+ NT NT NT
+ - + +
+ NT NT NT
NT NT - +
NT NT - +
+ + -
+ + NT NT
+ - + +














23746-34-1 BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM
1937-37-7 C.I. DIRECT BLACK 38
2784-94-3 HC BLUE NO. 1
2475-45-8 C.I. DISPERSE BLUE 1
2602-46-2 C.I. DIRECT BLUE 6
7758-01-2 BROMATE, POTASSIUM






















63449-39-8 CHLORINATED PARAFFINS (C12, 60% CHLORINE)
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Table 1. (Continued)
Rat Mouse MR FR MM FM CAS Name
+ NT NT NT
B+ B+ NT NT
+ NT NT NT
+ NT NT NT
+ + I -
+ + + +
+ + + +
B- B- + +
NT NT + NT
+ + + +
+
NT + + +
+ + +
_
A - + +
_ + +
+ + + +
+ + NT NT
T N+ NT NT
NT NT + -
NT NT + +
NT NT + +
T N+ NT NT
+ + + +
+ + - +
+ NT + +
NT NT + NT
+ NT NT NT
+ + + +
+ NT + +
+ + + +
+ + + +
NT + NT NT
NNT T + NT
_ E
+ +
+ + + +
+ + NT NT
NT NT NT +
+ + + +
_ _ + +
+ NT NT NT
+ NT NT NT
+ NT NT NT
+ - + +
+ + _ _
NT NT + +
NT NT + +
NT + NT NT
B+ B+ NT NT
B+ B+ + +
+ NT NT NT
+ NT + -
+ +
NT + NT NT
+ E - -
NT + NT NT
NT + NT NT
NT + NT NT
NT NT NT +
NT NT NT +
NT NT + +
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MR FR MM FM
NT + NT NT
+ + NT' NT
NT + NT NT
NT NT + +
+ + + +
NT NT + +
NT NT - +
NT NT NT +
_ _ + +
NT NT NT +
NT + NT NT NT
+ NT NT NT
+ - NT -
NT NT + +
NT NT B+ B+
+ + NT NT
NT NT + +
+ + NT NT
+ + + -
- N + +
+ + + +
NT NT + +
+ + NT NT
NT NT NT +
NT + NT NT
NT NT + +
+ NT NT NT
+ + NT NT
+ + NT NT
+ + + -
NT + NT NT
+ + NT +
NT NT + +
+ + - _
B+ B+ - _
NT NT + -
- + + +
B+ B+ NT NT
_ _ + +
NTNT + + +
+ + NT NT
NT NT + NT
+ NT + NT
NT NT + +
_ _ + +
_ _ + +
NT + NT NT
+
NT NT + +
+ + + +
NT + NT +
NT + NT +
NT + NT +
+ + - +
NT NT B+ B+
+ + NT +
NT NT NT +
NT + NT NT
1.52 NT + NT NT NT



































:32852-21-4 FORMIC ACID 2-(4-METHYL-2-THIAZOLYL,)HYDRAZIDE
:3570-75-0 FORMIC ACID 2- 4-(5-NITRO-2-FtTRYL)-2-THIAZOLYL
HYDRAZIDE
624-84-0 FORMYLHYDRAZINE
4680-78-8 FD & C GREEN NO. 1
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lTble 1. (Continued)











































































































































































































NITRILOTRIACETIC ACID, TRISODIUM SALT,
MONOHYDRATE
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Table 1. (Continued) ____________-
MR FR MM FM CAS Name
+ + - - 7632-00-0 NITRITE, SODIUM
- - + - 1777-84-0 3-NITRO-p-ACETOPHENETIDE
+ + - + 99-59-2 5-NITRO-o-ANISIDINE
NT + NT NT 59-87-0 5-NITRO-2-FURALDEHYDE SEMICARBAZONE
+ + + + 75198-31-1 3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE
NT + NT NT 2122-86-3 5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL
NT + NT NT 36133-88-7 N- 13-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL -
METHYLIACETAMIDE
NT + NT + 2578-75-8 N-15-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL
ACETAMIDE
NT + NT NT 53757-28-1 4-(5-NITRO-2-FURYL)THIAZOLE
NT + NT NT 531-82-8 N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIACETAMIDE
+ + + + 24554-26-5 N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE
NT + NT NT 51325-35-0 N,N'-16-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL
BISACETAMIDE
B+ B+ B+ B+ 4812-22-0 3-NITRO-3-HEXENE
- - - + 5307-14-2 2-NITRO-p-PHENYLENEDIAMINE
- - + + 99-55-8 5-NITRO-o-TOLUIDINE
+ + - + 602-87-9 5-NITROACENAPHTHENE
- - + + 94-52-0 6-NITROBENZIMIDAZOLE
I + + + 1836-75-5 NITROFEN
NT + NT NT 555-84-0 1-1(5-NITROFURFURYLIDENE)AMINOI-2-IMIDAZOLIDINONE
+ NT NT NT 51-75-2 NITROGEN MUSTARD
+ NT NT NT 126-85-2 NITROGEN MUSTARD N-OXIDE
+ + NT NT 607-35-2 8-NITROQUINOLINE
+ NT NT NT 38777-13-8 NITROSO-BAYGON
+ + NT NT --- N-NITROSO-BIS-(4,4,4-TRIFLUORO-N-BUTYL)AMINE
+ + NT NT 16813-36-8 1-NITROSO-5,6-DIHYDROURACIL
NT + NT NT 89911-79-5 N-NITROSO-2,3-DIHYDROXYPROPYL-2-
HYDROXYPROPYLAMINE
NT + NT NT 92177-50-9 NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE
NT + NT NT 89911-78-4 N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE
NT + NT NT 61034-40-0 1-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE
NT + NT NT 75896-33-2 N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE
B+ B+ NT NT 56222-35-6 N-NITROSO-3-HYDROXYPYRROLIDINE
NT + NT NT 760-60-1 N-NITROSO-N-ISOBUTYLUREA
+ + NT NT 55090-44-3 N-NITROSO-N-METHYL-N-DODECYLAMINE
+ NT NT NT 937-25-7 N-NITROSO-N-METHYL-4-FLUOROANILINE
+ NT NT NT 13256-11-6 NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE
+ NT NT NT 75881-20-8 N-NITROSO-N-METHYL-N-TETRADECYLAMINE
+ NT NT NT 75881-22-0 N-NITROSO-N-METHYLDECYLAMINE
NT + NT NT 92177-49-6 NITROSO-2-OXOPROPYLETHANOLAMINE
+ NT NT NT 15973-99-6 DI(N-NITROSO)-PERHYDROPYRIMIDINE
NT + NT NT 55556-92-8 NITROSO-1,2,3,6-TETRAHYDROPYRIDINE
+ NT NT NT 82018-90-4 N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE
+ NT NT NT 29929-77-9 N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE
POLYMER
NT + NT NT 75881-18-4 1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE
NT + NT NT 88208-16-6 N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE
NT + NT NT 91308-70-2 N-NITROSOALLYL-2-HYDROXYPROPYLAMINE
NT + NT NT 91308-71-3 N-NITROSOALLYL-2-OXOPROPYLAMINE
NT + NT NT 91308-69-9 N-NITROSOALLYLETHANOLAMINE
NT + NT NT --- NITROSOAMYLURETHAN
+ + NT NT 1133-64-8 NITROSOANABASINE
B+ B+ NT NT 51542-33-7 N-NITROSOBENZTHIAZURON
+ + NT NT 53609-64-6 N-NITROSOBIS(2-HYDROXYPROPYL)AMINE
+ + NT NT 60599-38-4 N-NITROSOBIS(2-OXOPROPYL)AMINE
+ NT + NT 924-16-3 NITROSODIBUTYLAMINE
+ + NT NT 1116-54-7 N-NITROSODIETHANOLAMINE
+ + NT NT 55-18-5 N-NITROSODIETHYLAMINE
+ + + + 62-75-9 N-NITROSODIMETHYLAMINE
+ + - - 86-30-6 N-NITROSODIPHENYLAMINE
+ - + - 156-10-5 p-NITROSODIPHENYLAMINE
NT + NT NT 621-64-7 N-NITROSODIPROPYLAMINE
+ + NT NT 40580-89-0 NITROSODODECAMETHYLENEIMINE



















































































































266SUMMARY OF CARCINOGENIC POTENCY
Tlble 1. (Continued)
Rat Mouse MR FR MM FM CAS Name
+ NT NT NT
NT + NT NT
+ NT NT NT
NT NT + +
+ + NT NT
NT + NT NT
+ + NT NT
NT + NT NT
+ + NT NT
+ NT NT NT
+ + NT NT
+ + NT NT
B+ B+ + NT
+ + NT NT
+ + NT NT
+ NT NT NT
B+ B+ NT +
NT + NT NT
+ + + +
A - + +
NT NT - +
+ + NT NT
+ + + +
+ NT NT NT
+ + - +
+ + +
+ +
+ + + +
+ + + +
B+ B+ NT NT
+ + _-
+ NT + +
NT NT - +
+ + NT NT
NT NT + +
+ NT - -
+ NT - -
NNT T - +
+ + _-
+ + + +
+ NT NT NT
+ + + +
+ + NT NT
NT + + +
NT NT + +
+ NT NT NT
+ + + +
NT NT + +
+ + B+ B+
B+ B+ NT NT
+ + NT NT
+ +
_-
+ + + +
+ A - -
+ + NT NT
B+ B+ NT NT
B+ B+ B- B-
+ - + +
+ +
























































3761-53-3 D & C RED NO. 5
5160-02-1 D & C RED NO. 9
3564-09-8 FD & C RED NO. 1
915-67-3 FD & C RED NO. 2
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A - - +
A _
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- NT - +
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+ - - +
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C.I. DISPERSE YELLOW 3
C.I. VAT YELLOW 4
ZEARALENONE
ZINC DIMETHYLDITHIOCARBAMATE
ZINC ETHYLENEBISTHIOCARBAMATE __- _v__ __ _ . _ __ _1 -. 1^ .......... . ^ . .........-..(otneonxtpg
(Continued on next page)
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Table 1. (Continued)
TD50 value:
For each species, the reported TD50 value is the most potent in the CPDB from among sites that a published author evaluated as
positive. This TD-0 was selected from those with a statistically significant dose response effect (two-tailed p<O.1). If no site
evaluated as positive was significant, then the reported TDr() was the most potent among those positive sites, and the footnote "b"
indicates that p(t).l1 .
Abbre%iations:
CAS = Chemical Abstracts Serxvice registry number
NT = No Test in the CPDB in this group
+ = The CPDB contains at least one experiment in which the compound was evaluated as a carcinogen by the published
author. Foi NCI/NTP tests, the evaluation was "clear evidence of carcinogenicity."
I = No tests in the CPDB in this sex-species group were evaluated as positive, however, the NCI/NTP test was evaluated as
inadequate.
A = 'I'he chemical was evaluated as a carcinogen in at least one test in the CPDB, but not in this sex-species group. However,
the NCI evaluated the compounId in this sex-species group as "associated with carcinogenicity" in their test, or the NTP
evaluated it as having "some evidence of carcinogenicity."
E The chemical was evaluated as a carcinogen in at least one test in the CPDB, but not in this sex-species group. The only
evidence for carcinogenicity in the CPDB for this sex-species group was an "equivocal" evaluation by the NTP.
- = The chemical was evaluated as a carcinogen in at least one test in the CPDB but all test.s in this group were negative.
B+ = In the only positive test in the sex-species, results were reported only for males and f'emales combined.
B- = In the only test in the sex-species, results were reported only for males and females combined, and the test was negative.
Footnotes:
a = The ClPDB contains more than one positive test in the species.
h = The reported TD50 is nlOt statistically significant (i.e. p>O.l), and all positivelv evaluated results in the species are not
signif'icanit.
c = Gnly an upper bound and no TD50 could be estimated because all dosed animals had the tumor of interest and only sum-
mary data were available. The reported value is the 99%O upper confidence limit.
d = All positive results in the CPDB are from tests in which the compound was administered by either intraperitoneal or
intravenous injection.
e = The reported TD50 is from a test in which the compound was administered by intraperitoneal or intravenous injection;
however, the CPDB also contaiins a positive test with a less potent TD50 value from a test with an oral or inhalation
route.
= TD5() values from different significant, positive experiments in this species vary by more than ten-fold f'rom one another.
The most potent TD-0 value is reported here.
26'9GOLD, SLONE, AND BERNSTEIN
chemicals among the 955 chemicals in the CPDB that
were tested in rats or mice. The table provides
information for each substance on the most potent
TD50 value in each species, the strength of evidence for
carcinogenicity in each sex-species group, and the
Chemical Abstracts Service (CAS) registry number.
Forty-six percent of these chemicals were tested in both
rats and mice, 35% in rats only, and 19% in mice only.
The positivity results for the 492 compounds can be
summarized as follows: 342 are positive in rats, and
278 are positive in mice. Among the 228 carcinogens
tested in both rats and mice, 100 (44%) are positive in
only one species. One hundred sixty-two chemicals
were tested in all four sex-species groups, and 52 (32%)
of these are positive in all four. Only 133 (27%) of the
carcinogens listed in Table 1 were tested in the
NCI/NTP Bioassay Program. A detailed analysis of
positivity and target sites in the CPDB can be found in
Gold etal. (7).
The distribution of TD50 values in Table 1 is
summarized in Figure 1. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (86.8 ng/kg/day) and C.I. Vat Yellow 4 (10.9
g/kg/day) represent the minimum and maximum
TD50 values for mice. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (6.67 ng/kg/day) and SX Purple (24.5 g/kg/
day) represent the minimum and maximum values
for rats. Among the 128 chemicals in Table 1 that are
positive in both species, the TD50 in rats is more potent
than the value in mice for 88, and less potent for 40.
Species differences in potency values (in mg/kg/day)
are within a factor of 10 for 95 of the 128 compounds
(74%). A similar proportion has been reported for
chemicals administered in the diet, using the lowest
TD50 per species regardless ofthe author's evaluation of
carcinogenicity or statistical significance (12).
Rats (N = 342)
Discussion
Summary Measures of Carcinogenic
Potency
In Table 1 we selected the TD50 value from one case,
the most potent, to represent a chemical within a
species. When more than one experiment fulfilled the
selection criteria, other summary measures of TD50
could have been used that take into account all positive
results for a compound. We evaluated three summary
measures: the harmonic mean, the geometric mean,
and the arithmetic mean to determine how different
our results would have been had we used one of these
measures. These measures differ according to the
weight given outlying results. If we define, Ti, i = 1,n, to
be the n values of TD50 that fulfill the selection criteria




the geometric mean, TG, is defined as
TG=
and the arithmetic mean, TA, is defined as
I ni
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270SUMMARY OF CARCINOGENIC POTENCY
Means based on these measures can be ordered in terms
oftheir relationship to our most potent site, Tp:
TP. TH <TG < TA
Table 2 shows the distribution of values of the ratios
TH/Tp, TG/Tp, and TA/Tp for rats and mice forchemicals
that have more than one positive test in a species; Table
2 therefore includes one-half of the rat carcinogens in
Table 1 and two-thirds of those in mice. The
remaining chemicals in Table 1 have only one positive
test. Those compounds for which we obtained a 10-fold
or greater discrepancy in these ratios are listed in the
footnote to Table 2. We have selected Tpfor presentation
in Table 1. One could have chosen the harmonic or
other forms ofthe mean for presentation since they take
the results of all positive experiments into account. For
various purposes one may wish to use different
summary measures; however, as we show in Table 2, it
makes little difference whether the choice is the most
potent site or a mean. The TD50 values used to compute
summary estimates can be found in Gold et al. (4-6).
Chemicals with Widely Varying TD50
Estimates
To further indicate particular substances for which
TD50 values from two or more experiments differ
greatly, we denote in Table 1 those chemicals for which
the minimum estimate differs from the maximum
estimate by more than a factor of 10 (see footnote f to
Table 1). There are 18 such substances in rats and 12 in
mice. For these carcinogens, any summary measure of
Table 2. Ratio of harmonic, geometric, and arithmetic
means to most potent TD50 for chemicals positive in more







polenlt H G A H G A
1-1.99 88 74 61 92 78 72
2-2.99 9 15 19 7 14 12
3-3.99 2 3 7 0 7 6
4-9.99 1 6 9 1 1 8
1-0 0 2a 4a 0 0 ° a
Total 100Ic 1001 100% 10 0oo i 100o> 100%
potency masks the variation across experiments.
While noting that the number of such cases is small,
we have investigated possible reasons for these widely
differing potency estimates for a chemical within a
species. We first compared the frequency of estimates
varying more than 10-fold to the frequency observed
for near-replicate experiments (Table 3). In an earlier
paper (6), we examined reproducibility of results in 66
comparisons consisting of 2 or more bioassays of the
same chemical administered by the same route and
using the same sex and strain of rat or mouse. Here we
update this analysis to include 35 additional com-
parisons from our more recent plots of the CPDB (5,6).
Overall, there was good reproducibility of positivity:
among the 101 comparisons, 51 were concordant and
positive in all of the near-replicate tests, 35 were
concordant and negative, and 15 were discordant. For
each species, we took the ratio of the least potentTD50
and the most potent TD50 in each concordant-positive
near-replicate case, and we compared the distribution
of these ratios to the distribution of all chemicals
having more than one positive experiment, i.e., those
chemicals reported in Table 2. (The chemicals with
near-replicate tests are also included in the larger
distribution, but the TD50 values for those substances
may be from different experiments.) Table 3 indicates
that the distribution of the ratio of least to most potent
TD50 values for all chemicals is similar to that for the
near-replicate comparisons. This similarity suggests
that the discrepant results for a chemical within a
species are not an artifact of combining across strains,
routes of administration, and sexes.
We also compared the extreme cases (TD50 values
discrepant by > 10-fold) to all other chemicals in Table 1
with more than one positive experiment, in terms of
how often they were tested. In mice, 92% of the extreme
cases were tested more than twice compared to 33% ofall
other cases; in rats, 89% of extremes were tested more
than twice compared to 42% of others. There are similar
differences in the number of positive tests for the two
groups. Thus, when there are extreme differences
between TD50 values from different tests of the same
chemical, the selection of the least and most potent
Table 3. Ratio of least to most potent TD50 from different
positive experiments for near-replicate comparisons and
all chemicals with more than one positive experiment, by
species.
Legend:
H = Ratio of harmonic mean (TH) to most potent TD50 (Tp)
G = Ratio of geometric mean (TG) to most potent TD50 (Tp)
A = Ratio of arithmetic mean (TA) to most potent TD50 (Tp)
aChemicals with values of ratio greater than 10. Those followed by "
were in the extreme category for both arithmetic and geometric means.
Rats:
AF-2; Aflatoxin B1; Aniline.HCl; Nitrosomethylaniline (*);








Near-replicate All Near-replicate All
tests chemicals tests chemicals
N (%) N (%) N (S) N (%)
1-1.99 15 (55) 76 (46) 13 (54) 90 (51)
2-2.99 4 (15) 21 (13) 6 (25) 35 (20)
3-3.99 3 (11) 19 (12) 0 ( 0) 11 ( 6)
4-9.99 2 ( 8) 29 (18) 4 (17) 28 (16)
.10 3 (11) 18 (11) 1 ( 4) 12 ( 7)
27 (100) 163 (100) 24 (100) 176 (100)
271
Total272 GOLD, SLONE, AND BERNSTEIN
values was made from among a larger number of TD50
values.
Finally, we investigated whether differences between
the dose levels administered in the comparison tests
were greater for the extreme cases. Generally, within a
species the doses in different tests of the same chemical
are quite similar. We computed the ratio of maximum
doses tested in the experiments that yielded the mini-
mum and maximum TD50 values. The median of this
ratio for the cases that were not extreme (i.e., differed by
less than a factor of 10) was 1.09 for mice and 1.25 for
rats. We found that three-quarters of the extreme cases
with a ratio > 10 were above this median in each
species. This result is not surprising since generally
the TD50 value is restricted by the maximum dose
tested in a bioassay, i.e., a statistically significant TD50
cannot be very far from the administered dose, given
the usual experimental design (13).
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